{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:18:47Z","timestamp":1788013127006,"version":"build-2784847793"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,27]]},"DOI":"10.7759\/cureus.49533","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T07:13:44Z","timestamp":1701155624000},"source":"Crossref","is-referenced-by-count":3,"title":["Acute Tubulointerstitial Nephritis and Secondary Renal Amyloidosis: A Rare Complication of Atezolizumab"],"prefix":"10.7759","author":[{"given":"Naqib","family":"Ullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameen","family":"Bin Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mussadique Ali","family":"Jhatial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Awais","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad M","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Muzaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudassar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Fasih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020, 70:7-30. 10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocz230","article-title":"Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks","volume":"27","author":"Yu KH","year":"2020","unstructured":"Yu KH, Wang F, Berry GJ, R\u00e9 C, Altman RB, Snyder M, Kohane IS. Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks. J Am Med Inform Assoc. 2020, 27:757-69. 10.1093\/jamia\/ocz230","journal-title":"J Am Med Inform Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicenter, randomized, open-label, phase 3 trial","volume":"20","author":"West H","year":"2019","unstructured":"West H, McCleod M, Hussein M, et al.. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicenter, randomized, open-label, phase 3 trial. Lancet Oncol. 2019, 20:924-937. 10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"ref4","article-title":"Immune checkpoint inhibitor-associated renal amyloid A amyloidosis; A case series and review of literature","volume":"4","author":"Sebastian Lapman","year":"2020","unstructured":"Sebastian Lapman, William L Whittier, Rushang Parikh, et al.. Immune checkpoint inhibitor-associated renal amyloid A amyloidosis; A case series and review of literature. Journal of Onco-Nephrology. 2020, 4:52-58.","journal-title":"Journal of Onco-Nephrology"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1159\/000455014","article-title":"Cancer and kidney international network workgroup on immune check point inhibitors; adverse renal effects of immune check point inhibitors; a narrative review","volume":"45","author":"Wanchoo R","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, et al.. Cancer and kidney international network workgroup on immune check point inhibitors; adverse renal effects of immune check point inhibitors; a narrative review. Am J Nephrol. 2017, 45:160-169.","journal-title":"Am J Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney JH","year":"2013","unstructured":"Pinney JH, Smith CJ, Taube JB, et al.. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013, 161:525-32. 10.1111\/bjh.12286","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki K","year":"2012","unstructured":"Hemminki K, Li X, F\u00f6rsti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012, 12:974. 10.1186\/1471-2458-12-974","journal-title":"BMC Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1801663","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Kumar B","year":"2018","unstructured":"Kumar B, Ballas Z. Adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:1164. 10.1056\/NEJMc1801663","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164786","article-title":"Immune checkpoint inhibitors' associated renal toxicity: a series of 12 cases","volume":"11","author":"Palamaris K","year":"2022","unstructured":"Palamaris K, Alexandris D, Stylianou K, et al.. Immune checkpoint inhibitors' associated renal toxicity: a series of 12 cases. J Clin Med. 2022, 11:10.3390\/jcm11164786","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/199317-acute-tubulointerstitial-nephritis-and-secondary-renal-amyloidosis-a-rare-complication-of-atezolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:55Z","timestamp":1707509215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/199317-acute-tubulointerstitial-nephritis-and-secondary-renal-amyloidosis-a-rare-complication-of-atezolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.49533","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,27]]}}}